Aptose Biosciences

This company is a science-driven biotechnology company advancing first-in-class therapeutics to treat life-threatening cancers, such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Aptose is developing personalized medicines for accuracy treatment of these diseases, interested in a patient’s specific gene signature. Moreover, they are also making proprietary companion diagnostic devices to identify predisposed sensitivities to aimed therapies.

The Company’s lead program, APTO-253, induces expression of the silenced KLF4 gene, providing a new therapeutic approach for the treatment of this disease.

In addition, their group comprises accomplished industry, financial and clinical research professionals who are devoted to building a comprehensive anticancer drug pipeline and clinical development programs focused on aimed therapeutics.